English

BIODESIX, INC.

EDGAR

BDSX Quarterly report (10-Q) · filed 2026-08-05

Annual consolidated revenue for 2025: about USD 88.5M, using the latest reported figures. The previous period, 2024, was about USD 71.32M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

26.9 million USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 26861000 USD Source

Operating margin

-20.06%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -5388000 USD Source
Revenue: 26861000 USD Source

Operating cash flow

-1.56 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -11730000 USD Source
Operating Cash Flow: -10168000 USD Source

Free cash flow

-1.76 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -11730000 USD Source
Operating Cash Flow: -10168000 USD Source
Capital Expenditure: 278000 USD Source
Capital Expenditure: 81000 USD Source

Cash and cash equivalents: 30 million USD 2026-06-30 Source
Exact value

29996000 USD
Long-term debt including current maturities: 50 million USD 2026-06-30 Source
Exact value

50000000 USD
Shares outstanding: 10.5 million shares 2026-06-30 Source
Exact value

10549890 shares

Reported share-count change

-92.80% · -136 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

146584110 shares · 2025-06-30· Source
10549890 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

103 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 21768000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 88499000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 59744000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 25555000 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 26861000 USD · 2026-04-01 – 2026-06-30 Source

Net income

-27.8 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -8716000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -35265000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -31285000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -7793000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -7273000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-19.8 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -24049000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -15170000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -23271000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -24049000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -10168000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -11730000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -10168000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

412 thousand USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 173000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 125000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 259000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 173000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 81000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 278000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 81000 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-20.2 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -24049000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -15170000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -23271000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -24049000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -10168000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -11730000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -10168000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 173000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 125000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 259000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 173000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 81000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 278000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 81000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-05.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 7 of 11 periods available· newest 2025-12-31
Operating income: 7 of 11 periods available· newest 2025-12-31
Net income: 7 of 11 periods available· newest 2025-12-31
Operating cash flow: 7 of 11 periods available· newest 2025-12-31
Capital expenditure: 7 of 11 periods available· newest 2025-12-31
Total assets: 7 of 11 periods available· newest 2025-12-31
Total liabilities: 7 of 11 periods available· newest 2025-12-31
Current assets: 7 of 11 periods available· newest 2025-12-31
Current liabilities: 7 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 7 of 11 periods available· newest 2025-12-31
Long-term debt including current maturities: 6 of 11 periods available· newest 2025-12-31
Shares outstanding: 7 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+24.1%

Prior period

USD 71.32 million

2024-01-01 – 2024-12-31
Current period

USD 88.5 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

88499000 − 71323000 = 17176000 USD

71323000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
88499000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · BIODESIX, INC. · 2025-12-31 BIODESIX, INC. (edgar:1439725) Year-over-year change in Revenue: 17176000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T14:07:56Z Snapshot: 1b13331b9d503c7ea4550a045613fe3ca19abd69954e604f431ca88d32843666 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439725?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 88499000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000119312526076547/bdsx-20251231.htm#3284578 Filing: 000119312526076547 Input fundies:Revenue: 71323000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000119312526076547/bdsx-20251231.htm#3286204 Filing: 000119312526076547
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 7.67 million

Prior period

−USD 42.93 million

2024-01-01 – 2024-12-31
Current period

−USD 35.27 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-35265000 − -42931000 = 7666000 USD

-42931000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-35265000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · BIODESIX, INC. · 2025-12-31 BIODESIX, INC. (edgar:1439725) Year-over-year change in Net income: 7666000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T14:07:56Z Snapshot: 1b13331b9d503c7ea4550a045613fe3ca19abd69954e604f431ca88d32843666 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439725?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -35265000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000119312526076547/bdsx-20251231.htm#3333270 Filing: 000119312526076547 Input fundies:NetIncome: -42931000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000119312526076547/bdsx-20251231.htm#3335130 Filing: 000119312526076547
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 25.38 million

Prior period

−USD 48.65 million

2024-01-01 – 2024-12-31
Current period

−USD 23.27 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-23271000 − -48649000 = 25378000 USD

-48649000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-23271000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · BIODESIX, INC. · 2025-12-31 BIODESIX, INC. (edgar:1439725) Year-over-year change in Operating cash flow: 25378000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T14:07:56Z Snapshot: 1b13331b9d503c7ea4550a045613fe3ca19abd69954e604f431ca88d32843666 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439725?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -23271000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000119312526076547/bdsx-20251231.htm#2055127 Filing: 000119312526076547 Input fundies:OperatingCashFlow: -48649000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000119312526076547/bdsx-20251231.htm#2056878 Filing: 000119312526076547
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-92%

Prior period

USD 3.23 million

2024-01-01 – 2024-12-31
Current period

USD 259,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

259000 − 3230000 = -2971000 USD

3230000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
259000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · BIODESIX, INC. · 2025-12-31 BIODESIX, INC. (edgar:1439725) Year-over-year change in Capital expenditure: -2971000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T14:07:56Z Snapshot: 1b13331b9d503c7ea4550a045613fe3ca19abd69954e604f431ca88d32843666 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439725?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 259000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000119312526076547/bdsx-20251231.htm#2064176 Filing: 000119312526076547 Input fundies:CapitalExpenditure: 3230000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000119312526076547/bdsx-20251231.htm#2065915 Filing: 000119312526076547
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 88.5 million 100% of revenue
Operating costs Derived USD 116.37 million 131% of revenue
Operating income −USD 27.87 million −31% of revenue
Tax, interest and other Derived USD 7.39 million 8.4% of revenue
Net income −USD 35.27 million −40% of revenue

Cash

Operating cash flow −USD 23.27 million −26% of revenue
Capital expenditure USD 259,000 0.3% of revenue
Free cash flow Derived −USD 23.53 million −27% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2019 Operating loss: operating costs were 209% of revenue.
2020 Operating loss: operating costs were 150% of revenue.
2021 Operating loss: operating costs were 175% of revenue.
2022 Operating loss: operating costs were 232% of revenue.
2023 Operating loss: operating costs were 184% of revenue.
2024 Operating loss: operating costs were 148% of revenue.
2025 Operating loss: operating costs were 131% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2019 2019-01-01 – 2019-12-31	24552000	51293000 Derived	-26741000	3985000 Derived	-30726000	-23036000 Derived	Source 2019-01-01 – 2019-12-31: 24552000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -26741000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -30726000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -21726000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 1310000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	45557000	68491000 Derived	-22934000	42513000 Derived	-65447000	-23311000 Derived	Source 2020-01-01 – 2020-12-31: 45557000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -22934000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -65447000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -21366000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 1945000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	54506000	95446000 Derived	-40940000	2219000 Derived	-43159000	-30464000 Derived	Source 2021-01-01 – 2021-12-31: 54506000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -40940000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -43159000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -28223000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 2241000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	38212000	88799000 Derived	-50587000	14860000 Derived	-65447000	-48270000 Derived	Source 2022-01-01 – 2022-12-31: 38212000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -50587000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -65447000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -44972000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 3298000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	49087000	90429000 Derived	-41342000	10804000 Derived	-52146000	-45789000 Derived	Source 2023-01-01 – 2023-12-31: 49087000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -41342000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -52146000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -22870000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 22919000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	71323000	105821000 Derived	-34498000	8433000 Derived	-42931000	-51879000 Derived	Source 2024-01-01 – 2024-12-31: 71323000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -34498000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -42931000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -48649000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 3230000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	88499000	116372000 Derived	-27873000	7392000 Derived	-35265000	-23530000 Derived	Source 2025-01-01 – 2025-12-31: 88499000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -27873000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -35265000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -23271000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 259000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 88.5M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Revenue	24552000	Revenue: 24552000 Open source
20202020-12-31	Revenue	45557000	Revenue: 45557000 Open source
20212021-12-31	Revenue	54506000	Revenue: 54506000 Open source
20222022-12-31	Revenue	38212000	Revenue: 38212000 Open source
20232023-12-31	Revenue	49087000	Revenue: 49087000 Open source
20242024-12-31	Revenue	71323000	Revenue: 71323000 Open source
20252025-12-31	Revenue	88499000	Revenue: 88499000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

24.1% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Year over year	No prior comparable period	Revenue: 24552000 Open source
20202020-12-31	Year over year	85.6%	Revenue: 45557000 Open source Revenue: 24552000 Open source
20212021-12-31	Year over year	19.6%	Revenue: 54506000 Open source Revenue: 45557000 Open source
20222022-12-31	Year over year	-29.9%	Revenue: 38212000 Open source Revenue: 54506000 Open source
20232023-12-31	Year over year	28.5%	Revenue: 49087000 Open source Revenue: 38212000 Open source
20242024-12-31	Year over year	45.3%	Revenue: 71323000 Open source Revenue: 49087000 Open source
20252025-12-31	Year over year	24.1%	Revenue: 88499000 Open source Revenue: 71323000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -31.5% 2025

Net margin -39.8% 2025

Free cash flow margin -26.6% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Operating margin	-108.9%	Operating Income: -26741000 Open source Revenue: 24552000 Open source
20202020-12-31	Operating margin	-50.3%	Operating Income: -22934000 Open source Revenue: 45557000 Open source
20212021-12-31	Operating margin	-75.1%	Operating Income: -40940000 Open source Revenue: 54506000 Open source
20222022-12-31	Operating margin	-132.4%	Operating Income: -50587000 Open source Revenue: 38212000 Open source
20232023-12-31	Operating margin	-84.2%	Operating Income: -41342000 Open source Revenue: 49087000 Open source
20242024-12-31	Operating margin	-48.4%	Operating Income: -34498000 Open source Revenue: 71323000 Open source
20252025-12-31	Operating margin	-31.5%	Operating Income: -27873000 Open source Revenue: 88499000 Open source
20192019-12-31	Net margin	-125.1%	Net Income: -30726000 Open source Revenue: 24552000 Open source
20202020-12-31	Net margin	-143.7%	Net Income: -65447000 Open source Revenue: 45557000 Open source
20212021-12-31	Net margin	-79.2%	Net Income: -43159000 Open source Revenue: 54506000 Open source
20222022-12-31	Net margin	-171.3%	Net Income: -65447000 Open source Revenue: 38212000 Open source
20232023-12-31	Net margin	-106.2%	Net Income: -52146000 Open source Revenue: 49087000 Open source
20242024-12-31	Net margin	-60.2%	Net Income: -42931000 Open source Revenue: 71323000 Open source
20252025-12-31	Net margin	-39.8%	Net Income: -35265000 Open source Revenue: 88499000 Open source
20192019-12-31	Free cash flow margin	-93.8%	Revenue: 24552000 Open source Operating Cash Flow: -21726000 Open source Capital Expenditure: 1310000 Open source
20202020-12-31	Free cash flow margin	-51.2%	Revenue: 45557000 Open source Operating Cash Flow: -21366000 Open source Capital Expenditure: 1945000 Open source
20212021-12-31	Free cash flow margin	-55.9%	Revenue: 54506000 Open source Operating Cash Flow: -28223000 Open source Capital Expenditure: 2241000 Open source
20222022-12-31	Free cash flow margin	-126.3%	Revenue: 38212000 Open source Operating Cash Flow: -44972000 Open source Capital Expenditure: 3298000 Open source
20232023-12-31	Free cash flow margin	-93.3%	Revenue: 49087000 Open source Operating Cash Flow: -22870000 Open source Capital Expenditure: 22919000 Open source
20242024-12-31	Free cash flow margin	-72.7%	Revenue: 71323000 Open source Operating Cash Flow: -48649000 Open source Capital Expenditure: 3230000 Open source
20252025-12-31	Free cash flow margin	-26.6%	Revenue: 88499000 Open source Operating Cash Flow: -23271000 Open source Capital Expenditure: 259000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -23.3M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Operating cash flow	-21726000	Operating Cash Flow: -21726000 Open source
20202020-12-31	Operating cash flow	-21366000	Operating Cash Flow: -21366000 Open source
20212021-12-31	Operating cash flow	-28223000	Operating Cash Flow: -28223000 Open source
20222022-12-31	Operating cash flow	-44972000	Operating Cash Flow: -44972000 Open source
20232023-12-31	Operating cash flow	-22870000	Operating Cash Flow: -22870000 Open source
20242024-12-31	Operating cash flow	-48649000	Operating Cash Flow: -48649000 Open source
20252025-12-31	Operating cash flow	-23271000	Operating Cash Flow: -23271000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -23.5M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Free cash flow	-23036000	Operating Cash Flow: -21726000 Open source Capital Expenditure: 1310000 Open source
20202020-12-31	Free cash flow	-23311000	Operating Cash Flow: -21366000 Open source Capital Expenditure: 1945000 Open source
20212021-12-31	Free cash flow	-30464000	Operating Cash Flow: -28223000 Open source Capital Expenditure: 2241000 Open source
20222022-12-31	Free cash flow	-48270000	Operating Cash Flow: -44972000 Open source Capital Expenditure: 3298000 Open source
20232023-12-31	Free cash flow	-45789000	Operating Cash Flow: -22870000 Open source Capital Expenditure: 22919000 Open source
20242024-12-31	Free cash flow	-51879000	Operating Cash Flow: -48649000 Open source Capital Expenditure: 3230000 Open source
20252025-12-31	Free cash flow	-23530000	Operating Cash Flow: -23271000 Open source Capital Expenditure: 259000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

102.8% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Liabilities / assets	169.2%	Total Liabilities: 76213000 Open source Total Assets: 45033000 Open source
20202020-12-31	Liabilities / assets	66%	Total Liabilities: 79904000 Open source Total Assets: 121070000 Open source
20212021-12-31	Liabilities / assets	74.1%	Total Liabilities: 56370000 Open source Total Assets: 76097000 Open source
20222022-12-31	Liabilities / assets	77.8%	Total Liabilities: 72300000 Open source Total Assets: 92906000 Open source
20232023-12-31	Liabilities / assets	95.4%	Total Liabilities: 94516000 Open source Total Assets: 99096000 Open source
20242024-12-31	Liabilities / assets	78.5%	Total Liabilities: 76368000 Open source Total Assets: 97244000 Open source
20252025-12-31	Liabilities / assets	102.8%	Total Liabilities: 89941000 Open source Total Assets: 87476000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

1.86× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Current assets / current liabilities	0.56×	Current Assets: 12700000 Open source Current Liabilities: 22600000 Open source
20202020-12-31	Current assets / current liabilities	2.68×	Current Assets: 86140000 Open source Current Liabilities: 32125000 Open source
20212021-12-31	Current assets / current liabilities	1.51×	Current Assets: 43613000 Open source Current Liabilities: 28960000 Open source
20222022-12-31	Current assets / current liabilities	2.34×	Current Assets: 53334000 Open source Current Liabilities: 22839000 Open source
20232023-12-31	Current assets / current liabilities	1.19×	Current Assets: 39683000 Open source Current Liabilities: 33416000 Open source
20242024-12-31	Current assets / current liabilities	2.76×	Current Assets: 39484000 Open source Current Liabilities: 14317000 Open source
20252025-12-31	Current assets / current liabilities	1.86×	Current Assets: 32518000 Open source Current Liabilities: 17436000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2019 2019-01-01 – 2019-12-31	−USD 30.73 million Exact value Exact value: -30726000 USD 2019-01-01 – 2019-12-31: -30726000 USD Inspect Net Income Open source Share or cite Citation for Net Income · BIODESIX, INC. · 2019-12-31 BIODESIX, INC. (edgar:1439725) Net Income: -30726000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T14:07:56Z Snapshot: 1b13331b9d503c7ea4550a045613fe3ca19abd69954e604f431ca88d32843666 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439725/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -30726000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000156459021013512/bdsx-10k_20201231.htm#3976572 Filing: 000156459021013512 The citation records this snapshot. The page link may show a newer release later.	−USD 21.73 million Exact value Exact value: -21726000 USD 2019-01-01 – 2019-12-31: -21726000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BIODESIX, INC. · 2019-12-31 BIODESIX, INC. (edgar:1439725) Operating Cash Flow: -21726000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T14:07:56Z Snapshot: 1b13331b9d503c7ea4550a045613fe3ca19abd69954e604f431ca88d32843666 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439725/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -21726000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000156459021013512/bdsx-10k_20201231.htm#3068570 Filing: 000156459021013512 The citation records this snapshot. The page link may show a newer release later.	USD 1.31 million Exact value Exact value: 1310000 USD 2019-01-01 – 2019-12-31: 1310000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · BIODESIX, INC. · 2019-12-31 BIODESIX, INC. (edgar:1439725) Capital Expenditure: 1310000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T14:07:56Z Snapshot: 1b13331b9d503c7ea4550a045613fe3ca19abd69954e604f431ca88d32843666 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439725/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1310000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000156459021013512/bdsx-10k_20201231.htm#3079622 Filing: 000156459021013512 The citation records this snapshot. The page link may show a newer release later.	−USD 23.04 million Calculation and evidence -21726000 − 1310000 USD Exact free cash flow: -23036000 USD 2019-01-01 – 2019-12-31: -21726000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 1310000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · BIODESIX, INC. · 2019-12-31 BIODESIX, INC. (edgar:1439725) Free cash flow: -23036000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T14:07:56Z Snapshot: 1b13331b9d503c7ea4550a045613fe3ca19abd69954e604f431ca88d32843666 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439725?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -21726000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000156459021013512/bdsx-10k_20201231.htm#3068570 Filing: 000156459021013512 Input fundies:CapitalExpenditure: 1310000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000156459021013512/bdsx-10k_20201231.htm#3079622 Filing: 000156459021013512 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 65.45 million Exact value Exact value: -65447000 USD 2020-01-01 – 2020-12-31: -65447000 USD Inspect Net Income Open source Share or cite Citation for Net Income · BIODESIX, INC. · 2020-12-31 BIODESIX, INC. (edgar:1439725) Net Income: -65447000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T14:07:56Z Snapshot: 1b13331b9d503c7ea4550a045613fe3ca19abd69954e604f431ca88d32843666 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439725/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -65447000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000095017023006092/bdsx-20221231.htm#3918227 Filing: 000095017023006092 The citation records this snapshot. The page link may show a newer release later.	−USD 21.37 million Exact value Exact value: -21366000 USD 2020-01-01 – 2020-12-31: -21366000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BIODESIX, INC. · 2020-12-31 BIODESIX, INC. (edgar:1439725) Operating Cash Flow: -21366000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T14:07:56Z Snapshot: 1b13331b9d503c7ea4550a045613fe3ca19abd69954e604f431ca88d32843666 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439725/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -21366000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000095017022003495/bdsx-20211231.htm#2396884 Filing: 000095017022003495 The citation records this snapshot. The page link may show a newer release later.	USD 1.95 million Exact value Exact value: 1945000 USD 2020-01-01 – 2020-12-31: 1945000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · BIODESIX, INC. · 2020-12-31 BIODESIX, INC. (edgar:1439725) Capital Expenditure: 1945000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T14:07:56Z Snapshot: 1b13331b9d503c7ea4550a045613fe3ca19abd69954e604f431ca88d32843666 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439725/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1945000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000095017022003495/bdsx-20211231.htm#2406674 Filing: 000095017022003495 The citation records this snapshot. The page link may show a newer release later.	−USD 23.31 million Calculation and evidence -21366000 − 1945000 USD Exact free cash flow: -23311000 USD 2020-01-01 – 2020-12-31: -21366000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 1945000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · BIODESIX, INC. · 2020-12-31 BIODESIX, INC. (edgar:1439725) Free cash flow: -23311000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T14:07:56Z Snapshot: 1b13331b9d503c7ea4550a045613fe3ca19abd69954e604f431ca88d32843666 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439725?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -21366000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000095017022003495/bdsx-20211231.htm#2396884 Filing: 000095017022003495 Input fundies:CapitalExpenditure: 1945000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000095017022003495/bdsx-20211231.htm#2406674 Filing: 000095017022003495 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 43.16 million Exact value Exact value: -43159000 USD 2021-01-01 – 2021-12-31: -43159000 USD Inspect Net Income Open source Share or cite Citation for Net Income · BIODESIX, INC. · 2021-12-31 BIODESIX, INC. (edgar:1439725) Net Income: -43159000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:07:56Z Snapshot: 1b13331b9d503c7ea4550a045613fe3ca19abd69954e604f431ca88d32843666 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439725/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -43159000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000095017023006092/bdsx-20221231.htm#3920501 Filing: 000095017023006092 The citation records this snapshot. The page link may show a newer release later.	−USD 28.22 million Exact value Exact value: -28223000 USD 2021-01-01 – 2021-12-31: -28223000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BIODESIX, INC. · 2021-12-31 BIODESIX, INC. (edgar:1439725) Operating Cash Flow: -28223000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:07:56Z Snapshot: 1b13331b9d503c7ea4550a045613fe3ca19abd69954e604f431ca88d32843666 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439725/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -28223000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000095017023006092/bdsx-20221231.htm#2623481 Filing: 000095017023006092 The citation records this snapshot. The page link may show a newer release later.	USD 2.24 million Exact value Exact value: 2241000 USD 2021-01-01 – 2021-12-31: 2241000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · BIODESIX, INC. · 2021-12-31 BIODESIX, INC. (edgar:1439725) Capital Expenditure: 2241000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:07:56Z Snapshot: 1b13331b9d503c7ea4550a045613fe3ca19abd69954e604f431ca88d32843666 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439725/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2241000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000095017023006092/bdsx-20221231.htm#2634382 Filing: 000095017023006092 The citation records this snapshot. The page link may show a newer release later.	−USD 30.46 million Calculation and evidence -28223000 − 2241000 USD Exact free cash flow: -30464000 USD 2021-01-01 – 2021-12-31: -28223000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 2241000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · BIODESIX, INC. · 2021-12-31 BIODESIX, INC. (edgar:1439725) Free cash flow: -30464000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:07:56Z Snapshot: 1b13331b9d503c7ea4550a045613fe3ca19abd69954e604f431ca88d32843666 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439725?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -28223000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000095017023006092/bdsx-20221231.htm#2623481 Filing: 000095017023006092 Input fundies:CapitalExpenditure: 2241000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000095017023006092/bdsx-20221231.htm#2634382 Filing: 000095017023006092 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 65.45 million Exact value Exact value: -65447000 USD 2022-01-01 – 2022-12-31: -65447000 USD Inspect Net Income Open source Share or cite Citation for Net Income · BIODESIX, INC. · 2022-12-31 BIODESIX, INC. (edgar:1439725) Net Income: -65447000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:07:56Z Snapshot: 1b13331b9d503c7ea4550a045613fe3ca19abd69954e604f431ca88d32843666 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439725/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -65447000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000095017024023513/bdsx-20231231.htm#2837637 Filing: 000095017024023513 The citation records this snapshot. The page link may show a newer release later.	−USD 44.97 million Exact value Exact value: -44972000 USD 2022-01-01 – 2022-12-31: -44972000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BIODESIX, INC. · 2022-12-31 BIODESIX, INC. (edgar:1439725) Operating Cash Flow: -44972000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:07:56Z Snapshot: 1b13331b9d503c7ea4550a045613fe3ca19abd69954e604f431ca88d32843666 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439725/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -44972000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000095017024023513/bdsx-20231231.htm#1953714 Filing: 000095017024023513 The citation records this snapshot. The page link may show a newer release later.	USD 3.3 million Exact value Exact value: 3298000 USD 2022-01-01 – 2022-12-31: 3298000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · BIODESIX, INC. · 2022-12-31 BIODESIX, INC. (edgar:1439725) Capital Expenditure: 3298000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:07:56Z Snapshot: 1b13331b9d503c7ea4550a045613fe3ca19abd69954e604f431ca88d32843666 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439725/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3298000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000095017024023513/bdsx-20231231.htm#1960315 Filing: 000095017024023513 The citation records this snapshot. The page link may show a newer release later.	−USD 48.27 million Calculation and evidence -44972000 − 3298000 USD Exact free cash flow: -48270000 USD 2022-01-01 – 2022-12-31: -44972000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 3298000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · BIODESIX, INC. · 2022-12-31 BIODESIX, INC. (edgar:1439725) Free cash flow: -48270000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:07:56Z Snapshot: 1b13331b9d503c7ea4550a045613fe3ca19abd69954e604f431ca88d32843666 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439725?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -44972000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000095017024023513/bdsx-20231231.htm#1953714 Filing: 000095017024023513 Input fundies:CapitalExpenditure: 3298000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000095017024023513/bdsx-20231231.htm#1960315 Filing: 000095017024023513 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 52.15 million Exact value Exact value: -52146000 USD 2023-01-01 – 2023-12-31: -52146000 USD Inspect Net Income Open source Share or cite Citation for Net Income · BIODESIX, INC. · 2023-12-31 BIODESIX, INC. (edgar:1439725) Net Income: -52146000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T14:07:56Z Snapshot: 1b13331b9d503c7ea4550a045613fe3ca19abd69954e604f431ca88d32843666 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439725/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -52146000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000095017025030835/bdsx-20241231.htm#3268226 Filing: 000095017025030835 The citation records this snapshot. The page link may show a newer release later.	−USD 22.87 million Exact value Exact value: -22870000 USD 2023-01-01 – 2023-12-31: -22870000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BIODESIX, INC. · 2023-12-31 BIODESIX, INC. (edgar:1439725) Operating Cash Flow: -22870000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T14:07:56Z Snapshot: 1b13331b9d503c7ea4550a045613fe3ca19abd69954e604f431ca88d32843666 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439725/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -22870000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000095017025030835/bdsx-20241231.htm#2055091 Filing: 000095017025030835 The citation records this snapshot. The page link may show a newer release later.	USD 22.92 million Exact value Exact value: 22919000 USD 2023-01-01 – 2023-12-31: 22919000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · BIODESIX, INC. · 2023-12-31 BIODESIX, INC. (edgar:1439725) Capital Expenditure: 22919000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T14:07:56Z Snapshot: 1b13331b9d503c7ea4550a045613fe3ca19abd69954e604f431ca88d32843666 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439725/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 22919000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000095017025030835/bdsx-20241231.htm#2063498 Filing: 000095017025030835 The citation records this snapshot. The page link may show a newer release later.	−USD 45.79 million Calculation and evidence -22870000 − 22919000 USD Exact free cash flow: -45789000 USD 2023-01-01 – 2023-12-31: -22870000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 22919000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · BIODESIX, INC. · 2023-12-31 BIODESIX, INC. (edgar:1439725) Free cash flow: -45789000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T14:07:56Z Snapshot: 1b13331b9d503c7ea4550a045613fe3ca19abd69954e604f431ca88d32843666 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439725?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -22870000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000095017025030835/bdsx-20241231.htm#2055091 Filing: 000095017025030835 Input fundies:CapitalExpenditure: 22919000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000095017025030835/bdsx-20241231.htm#2063498 Filing: 000095017025030835 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 42.93 million Exact value Exact value: -42931000 USD 2024-01-01 – 2024-12-31: -42931000 USD Inspect Net Income Open source Share or cite Citation for Net Income · BIODESIX, INC. · 2024-12-31 BIODESIX, INC. (edgar:1439725) Net Income: -42931000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T14:07:56Z Snapshot: 1b13331b9d503c7ea4550a045613fe3ca19abd69954e604f431ca88d32843666 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439725/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -42931000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000119312526076547/bdsx-20251231.htm#3335130 Filing: 000119312526076547 The citation records this snapshot. The page link may show a newer release later.	−USD 48.65 million Exact value Exact value: -48649000 USD 2024-01-01 – 2024-12-31: -48649000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BIODESIX, INC. · 2024-12-31 BIODESIX, INC. (edgar:1439725) Operating Cash Flow: -48649000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T14:07:56Z Snapshot: 1b13331b9d503c7ea4550a045613fe3ca19abd69954e604f431ca88d32843666 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439725/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -48649000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000119312526076547/bdsx-20251231.htm#2056878 Filing: 000119312526076547 The citation records this snapshot. The page link may show a newer release later.	USD 3.23 million Exact value Exact value: 3230000 USD 2024-01-01 – 2024-12-31: 3230000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · BIODESIX, INC. · 2024-12-31 BIODESIX, INC. (edgar:1439725) Capital Expenditure: 3230000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T14:07:56Z Snapshot: 1b13331b9d503c7ea4550a045613fe3ca19abd69954e604f431ca88d32843666 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439725/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3230000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000119312526076547/bdsx-20251231.htm#2065915 Filing: 000119312526076547 The citation records this snapshot. The page link may show a newer release later.	−USD 51.88 million Calculation and evidence -48649000 − 3230000 USD Exact free cash flow: -51879000 USD 2024-01-01 – 2024-12-31: -48649000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 3230000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · BIODESIX, INC. · 2024-12-31 BIODESIX, INC. (edgar:1439725) Free cash flow: -51879000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T14:07:56Z Snapshot: 1b13331b9d503c7ea4550a045613fe3ca19abd69954e604f431ca88d32843666 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439725?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -48649000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000119312526076547/bdsx-20251231.htm#2056878 Filing: 000119312526076547 Input fundies:CapitalExpenditure: 3230000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000119312526076547/bdsx-20251231.htm#2065915 Filing: 000119312526076547 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 35.27 million Exact value Exact value: -35265000 USD 2025-01-01 – 2025-12-31: -35265000 USD Inspect Net Income Open source Share or cite Citation for Net Income · BIODESIX, INC. · 2025-12-31 BIODESIX, INC. (edgar:1439725) Net Income: -35265000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T14:07:56Z Snapshot: 1b13331b9d503c7ea4550a045613fe3ca19abd69954e604f431ca88d32843666 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439725/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -35265000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000119312526076547/bdsx-20251231.htm#3333270 Filing: 000119312526076547 The citation records this snapshot. The page link may show a newer release later.	−USD 23.27 million Exact value Exact value: -23271000 USD 2025-01-01 – 2025-12-31: -23271000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BIODESIX, INC. · 2025-12-31 BIODESIX, INC. (edgar:1439725) Operating Cash Flow: -23271000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T14:07:56Z Snapshot: 1b13331b9d503c7ea4550a045613fe3ca19abd69954e604f431ca88d32843666 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439725/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -23271000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000119312526076547/bdsx-20251231.htm#2055127 Filing: 000119312526076547 The citation records this snapshot. The page link may show a newer release later.	USD 259,000 Exact value Exact value: 259000 USD 2025-01-01 – 2025-12-31: 259000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · BIODESIX, INC. · 2025-12-31 BIODESIX, INC. (edgar:1439725) Capital Expenditure: 259000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T14:07:56Z Snapshot: 1b13331b9d503c7ea4550a045613fe3ca19abd69954e604f431ca88d32843666 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439725/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 259000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000119312526076547/bdsx-20251231.htm#2064176 Filing: 000119312526076547 The citation records this snapshot. The page link may show a newer release later.	−USD 23.53 million Calculation and evidence -23271000 − 259000 USD Exact free cash flow: -23530000 USD 2025-01-01 – 2025-12-31: -23271000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 259000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · BIODESIX, INC. · 2025-12-31 BIODESIX, INC. (edgar:1439725) Free cash flow: -23530000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T14:07:56Z Snapshot: 1b13331b9d503c7ea4550a045613fe3ca19abd69954e604f431ca88d32843666 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439725?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -23271000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000119312526076547/bdsx-20251231.htm#2055127 Filing: 000119312526076547 Input fundies:CapitalExpenditure: 259000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439725/000119312526076547/bdsx-20251231.htm#2064176 Filing: 000119312526076547 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

32 filings · 1,837 latest values · 1,837 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001439725, 1439725, BDSX, edgar:1439725

Also known as BIODESIX INC, BIODESIX, INC., Biodesix, Inc.

BIODESIX, INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation